echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Gastric Cancer: Effect of anticoagulants on the risk of delayed bleeding after gastric endoscoscopy.

    Gastric Cancer: Effect of anticoagulants on the risk of delayed bleeding after gastric endoscoscopy.

    • Last Update: 2020-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Endoscopic mucosal desorasis (ESD) is a general-purpose minimally invasive treatment for early gastric cancer (EGC) that is negative for lymph nodes and has relatively good long-term results compared to surgical treatment.
    , however, the incidence of post-ESD delayed bleeding is generally between 3.1% and 6.5%.
    However, we know that in an aging society, the number of patients taking antithrombotic drugs as a preventive therapy against cardiovascular disease is increasing year by year, so whether the risk of delayed bleeding after TREATMENT with ESD will increase is a question that we need to pay more attention to in the context of antithrombotic drugs (including anti-thrombosis and antiplatelet drugs).
    anticoagulants, including warfarin and directly active oral anticoagulants (DOACs), in the past, the preoperative discontinuation of heparin bridging therapy (HBT) and warfarin therapy to maximize the prevention of thrombotic surgery-related bleeding, but some studies have shown that the probability of gastrointestinal bleeding in patients treated by DOACs has not decreased.
    , in this study, researchers conducted a nationwide multicenter study in Japan comparing the clinical efficacy of various DOAC and conventional warfarin seismoration in the stomach.
    researchers reviewed 728 patients with stomach tumors who received anticoagulants and ESD treatment in 25 medical facilities in Japan. A total of 261 patients received DOAC in
    , including Dabiga Group (92), Levachaban (103), Apixaban (45) and Idosaban (21), while 467 patients received warfarin treatment.
    14% of patients taking DOAC had delayed bleeding, similar to those receiving warfarin (18%).
    patients treated with dabiga had significantly lower delayed bleeding rates than patients treated with warfarin and lower than in other DOAC patients.
    multi-factor analysis showed that the age of 65 years, receiving a variety of anti-suppositories, multiple lesions and lesions size of 30 mm are independent risk factors, and the discontinuation of anticoagulants and bleeding risk is associated.
    multivariate analysis in patients receiving DOAC, dabiga group therapy was associated with a significantly reduced risk of delayed bleeding.
    : The probability of delayed bleeding after various drugs ESD finally researchers said: DOAC's effect on delayed bleeding varies from drug to drug, but dabbiga therapy is associated with the lowest risk of delayed bleeding.
    changing oral anticoagulants to dabiga during perioperative may be a reasonable option to reduce the risk of delayed bleeding after gastric ESD.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.